Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis

Biao Li,1,* Jingjing Yang,1,* Jing Li,2,* Jiajia Huang,1 Zhiming Li1 1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republ...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Li B, Yang J, Li J, Huang J, Li Z
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Dove Medical Press 2026-05-01
Schriftenreihe:	ClinicoEconomics and Outcomes Research
Schlagworte:	Classical Hodgkin Lymphoma Nivolumab-AVD brentuximab vedotin-AVD Quality-adjusted life-years Incremental cost‐effectiveness ratio.
Online-Zugang:	https://www.dovepress.com/nivolumab-avd-versus-brentuximab-vedotin-avd-as-first-line-treatment-f-peer-reviewed-fulltext-article-CEOR
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!